南方医科大学学报 ›› 2013, Vol. 33 ›› Issue (05): 750-.

• • 上一篇    下一篇

乳腺癌原发灶B淋巴细胞浸润与预后的关系

于海明,杨俊兰,焦顺昌,王建东   

  • 出版日期:2013-05-20 发布日期:2013-05-20

Prognostic value of B lymphocyte infiltration in breast cancer

  • Online:2013-05-20 Published:2013-05-20

摘要: 目的探讨早期乳腺癌原发灶B细胞与临床病理特征以及预后的关系。方法回顾性收集2000年1月~2002年12月在解
放军总医院手术的130例Ⅰ~Ⅲ期乳腺癌患者的临床资料及石蜡切片,用免疫组织化学法检测乳腺癌原发灶间质中CD20阳性
B淋巴细胞的浸润情况并分析其与CD8和CD4阳性淋巴细胞密度的关系,以及分析CD20阳性细胞浸润与乳腺癌临床病理特
征及预后的关系。结果在部分乳腺癌(37.69%,49/130)间质可见CD20+B细胞聚集分布,并可观察到CD3+T细胞聚集在CD20+
B细胞聚集区的周围形成淋巴滤泡样结构。总体分析时,CD20+细胞聚集与预后不相关。在激素受体阴性(雌激素受体和孕激
素受体均为阴性)患者的COX多元分析中,CD20+细胞聚集与较好的DDFS(HR=0.251,95% CI=0.071-0.894,P=0.033)、OS
(HR=0.325,95%CI=0.103-1.028,P=0.056)相关。而在激素受体阳性(雌激素受体和孕激素受体至少有一个阳性)患者,CD20+
细胞聚集与DFS(P=0.997)、DDFS(P=0.759)、OS(P=0.700)均不相关。在激素受体阳性患者,术后辅助内分泌治疗可显著改善
CD20+细胞聚集阴性患者的OS(P=0.001)。结论CD20+细胞聚集在激素受体阴性乳腺癌患者有预后预测价值。术后辅助内分
泌治疗的远期疗效与乳腺癌原发灶CD20+细胞聚集相关,并进而影响CD20+细胞聚集与乳腺癌预后的关系。

Abstract: Objective To assess the prognostic value of CD20+ tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer.
Methods Paraffin sections were collected from 130 cases of stage I-III breast cancer undergoing surgery between January, 2000
and December, 2002 in our hospital. Immunohistochemistry was used to analyze mesenchymal CD20+ TILs infiltration in the
tumor and evaluate its association with the density of CD4+ and CD8+ TILs. The association of CD20+ TILs was evaluated with
the histopathologic features, overall survival (OS), distant disease-free survival (DDFS), and disease-free survival (DFS) of the
patients. Results Aggregations of CD20+ lymphocytes were observed in 37.69% (49/130) of the cases. CD3+ T cells were found to
aggregate around CD20+ B cell aggregations to form lymphoid follicle-like structures. The aggregations of CD20+ TILs were
positively correlated with the densities of mesenchymal CD8 + and CD4 + TILs. Overall, CD20 + TIL aggregations were not
significantly correlated with the outcomes of the patients, but multivariate COX regressions suggested that CD20 + TIL
aggregations were positively correlated with DDFS (HR=0.251, 95% CI=0.071-0.894, P=0.033) and OS (HR=0.325, 95% CI=
0.103-1.028, P=0.056) in hormone receptor-negative patients but not in the positive patients. Further analysis suggested that
post-operative adjuvant endocrine therapy significantly improved the OS of patients positive for hormone receptors without
CD20+ TIL aggregations (P=0.001). Conclusion The long-term therapeutic effects of adjuvant endocrine therapy are correlated
with CD20+ TIL aggregations to affect prognostic value of CD20+ TIL aggregations in early-stage breast cancer patients.